Australia Chooses Cardiac Science to Equip Its Defence Force
April 09 2008 - 6:30AM
PR Newswire (US)
BOTHELL, Wash., April 9, 2008 /PRNewswire-FirstCall/ -- Cardiac
Science Corporation (NASDAQ:CSCX), a global leader in advanced
cardiac diagnosis, resuscitation, rehabilitation, and informatics
products, announced it won a five-year contract from the Australian
Defence Force for the initial supply of 170 Powerheart(R) G3 Pro(R)
automated external defibrillators (AEDs) and accessories. The sale
adds to a string of international wins including a 100-unit
delivery to Eastern European military forces and a 300-unit
delivery for public access defibrillators for train stations in the
Netherlands. (Logo:
http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO) "We are
honored to support the service men and women of Australian Defence
Force with the durable Powerheart AED G3 Pro," said Kurt Lemvigh,
international vice president, Cardiac Science. "Australia's
confidence will be rewarded with dependable defibrillation,
ease-of-use, data transmission and connectivity, and 3-lead ECG
monitoring capabilities." The G3 Pro provides the industry's first
ECG color display, manual override features, multiple rescue
capability, and the most advanced technology for rescue
professionals' emergency treatment of sudden cardiac arrest.
Infrared data communications allow data from the AEDs to be
transmitted to a Windows PC, for ready connectivity and event
documentation. Cardiac Science is a leading AED supplier to
Australia. Working with the government and key Australian
organizations, Cardiac Science created significant awareness for
the need for public access defibrillation in the Australian market.
Now, a growing number of major corporations deploy Cardiac Science
AEDs on a large scale, protecting workplaces against sudden cardiac
arrest. All Powerheart AEDs feature patented Rescue Ready(R)
technology to run daily, weekly, and monthly self-tests of battery,
internal electronics, software, and pads. Rescue Ready tests
differentiate Powerheart devices among AEDs and ensure anytime
functionality and shock delivery. About the Australian Defence
Force The Australian Defence Force (ADF) is the military of
Australia. It consists of the Royal Australian Navy, Australian
Army, Royal Australian Air Force, and a number of additional joint
units. It includes 51,000 full-time active duty personnel and
19,400 reservists, of which 3,500 are deployed in multiple
locations across the world including Afghanistan, Sudan, Israel,
and Lebanon. About Cardiac Science Cardiac Science develops,
manufactures, and markets a family of advanced diagnostic and
therapeutic cardiology devices and systems, including automated
external defibrillators (AEDs), electrocardiograph devices (ECGs),
cardiac stress systems and treadmills, Holter monitoring systems,
hospital defibrillators, cardiac rehabilitation telemetry systems,
and cardiology data management systems (informatics) that connect
with hospital information (HIS), electronic medical record (EMR),
and other information systems. The Company sells a variety of
related products and consumables, and provides a portfolio of
training, maintenance, and support services. Cardiac Science, the
successor to the cardiac businesses that established the trusted
Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands,
is headquartered in Bothell, Washington. With customers in more
than 100 countries worldwide, the company has operations in North
America, Europe, and Asia. For information, call 425.402.2000 or
visit http://www.cardiacscience.com/. Forward-Looking Statements
This press release contains forward-looking statements including,
but not limited to, those that infer that Cardiac Science
Corporation's future revenue and profits may grow as a result of
sales of defibrillation products. These statements and their
underlying assumptions involve a number of risks and uncertainties
and are not guarantees of future performance. These are
forward-looking statements for purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "intend," anticipate,"
variations of such words, and similar expressions identify
forward-looking statements, but their absence does not mean that
the statement is not forward looking. Actual results may vary
significantly from the results expressed or implied in such
statements. Factors that could cause or contribute to such varying
results and other risks that are more fully described in the Annual
Report on Form 10-K filed by Cardiac Science Corporation for the
year ended December 31, 2007. Cardiac Science Corporation
undertakes no duty or obligation to update the information provided
herein. Company Contact: Investor Contact: Media Contact: Mike
Matysik Jenifer Kirtland Christopher Gale Cardiac Science
Corporation EVC Group, Inc. EVC Group, Inc. Sr. Vice President and
CFO (415) 896-6820 (201) 646-5431 (425) 402-2009 (203) 570-4681
CSCX-G http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO
http://photoarchive.ap.org/ DATASOURCE: Cardiac Science Corporation
CONTACT: Mike Matysik, Sr. Vice President and CFO of Cardiac
Science Corporation, +1-425-402-2009; or Investors, Jenifer
Kirtland, +1-415-896-6820, or Media, Christopher Gale,
+1-201-646-5431, +1-203-570-4681, , both of EVC Group, Inc., for
Cardiac Science Corporation Web site:
http://www.cardiacscience.com/
Copyright
Cardiac Science Corp (MM) (NASDAQ:CSCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cardiac Science Corp (MM) (NASDAQ:CSCX)
Historical Stock Chart
From Apr 2023 to Apr 2024